Bernina BioInvest

Versameb AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2018. The company specializes in the research and development of innovative RNA-based drugs aimed at modulating protein expression and enabling targeted cellular therapies. Versameb's proprietary technology platform, VERSagile, allows for the simultaneous influence of multiple therapeutic targets through a single molecular construct, optimizing the application of functional RNA across various disease contexts. Their pipeline includes candidate programs addressing stress urinary incontinence, solid tumors, and rare diseases. The company is advancing towards the completion of a first in-human proof-of-concept clinical study, leveraging the expertise of its experienced scientific and leadership team in drug discovery and development.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Versameb AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2018. The company specializes in the research and development of innovative RNA-based drugs aimed at modulating protein expression and enabling targeted cellular therapies. Versameb's proprietary technology platform, VERSagile, allows for the simultaneous influence of multiple therapeutic targets through a single molecular construct, optimizing the application of functional RNA across various disease contexts. Their pipeline includes candidate programs addressing stress urinary incontinence, solid tumors, and rare diseases. The company is advancing towards the completion of a first in-human proof-of-concept clinical study, leveraging the expertise of its experienced scientific and leadership team in drug discovery and development.

ELDICO Scientific AG is a Swiss company founded in 2019 and located at the Switzerland Innovation Park Innovaare, which is affiliated with the Paul Scherrer Institute. The company specializes in the development, manufacturing, and sale of electron diffractometers designed for the analysis of solid compounds, particularly targeting nano-crystalline systems in the sub-micrometer range. ELDICO's innovative instruments enable industrial and scientific researchers to characterize materials that were previously challenging to measure, thereby facilitating advancements in fields such as pharmaceuticals, agrochemicals, and advanced materials research. The company achieved proof of concept for its technology in 2018, with recognition from reputable scientific communities, including being named a Top 5 "Breakthrough of the Year" by a leading journal. This groundbreaking work positions ELDICO as a key player in enhancing the speed and cost-effectiveness of structural analysis, ultimately contributing to faster drug discovery and development processes.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of innovative immunotherapies aimed at enhancing cancer treatment and addressing autoimmune diseases. ImmunOs focuses on creating novel human immunomodulatory proteins that play a role in both innate and adaptive immunity. Their therapeutics are designed to exert direct anti-tumor effects by remodeling the tumor microenvironment, while also developing antibodies that inhibit the activation of specific HLA molecules linked to autoimmune conditions. Through its research and development efforts, ImmunOs aims to improve the lives of patients facing serious diseases.

ARTIDIS AG is a Swiss company founded in 2014, specializing in the development of innovative tissue diagnostic solutions for cancer therapy. The company has created the Automated Reliable Tissue Diagnostics (ARTIDIS), a nanomechanical diagnostic tool that assesses tissue samples from biopsies. This advanced system enables clinicians to differentiate between benign and malignant tissues in less than three hours, while also accurately determining tumor aggressiveness based on the nanomechanical signatures of the cells. ARTIDIS's technology leverages a nanomechanical sensor that captures the physical properties of tissues, facilitating the identification of biomarkers linked to disease progression. Although primarily focused on oncology, the company's technology can analyze any living tissue, offering a wide range of research and clinical applications. The combination of its tissue analysis device and integrated software provides actionable insights for treatment, ensuring that patients receive timely and accurate diagnoses at their bedside.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

Versameb AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2018. The company specializes in the research and development of innovative RNA-based drugs aimed at modulating protein expression and enabling targeted cellular therapies. Versameb's proprietary technology platform, VERSagile, allows for the simultaneous influence of multiple therapeutic targets through a single molecular construct, optimizing the application of functional RNA across various disease contexts. Their pipeline includes candidate programs addressing stress urinary incontinence, solid tumors, and rare diseases. The company is advancing towards the completion of a first in-human proof-of-concept clinical study, leveraging the expertise of its experienced scientific and leadership team in drug discovery and development.

InterAx Biotech Ltd is a biotechnology company based in Villigen, Switzerland, focused on developing a platform for the discovery of functionally selective drugs targeting G-Protein Coupled Receptors (GPCRs). Founded in 2016, the company integrates bioanalytical methods and computational pharmacology to assist in drug candidate design and selection. Its innovative platform combines high-throughput biochemical screening with artificial intelligence and mathematical modeling of cell signaling, facilitating the identification and optimization of drug candidates for various diseases, including those associated with orphan GPCRs. Through its advanced approach, InterAx Biotech aims to improve drug efficacy while reducing side effects, contributing to the healthcare industry's efforts to discover safer and more effective treatments.

Versameb AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2018. The company specializes in the research and development of innovative RNA-based drugs aimed at modulating protein expression and enabling targeted cellular therapies. Versameb's proprietary technology platform, VERSagile, allows for the simultaneous influence of multiple therapeutic targets through a single molecular construct, optimizing the application of functional RNA across various disease contexts. Their pipeline includes candidate programs addressing stress urinary incontinence, solid tumors, and rare diseases. The company is advancing towards the completion of a first in-human proof-of-concept clinical study, leveraging the expertise of its experienced scientific and leadership team in drug discovery and development.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.